SCHEMBL1307028

SCHEMBL1307028

CC(C)N(CCNCC(=Cc1ccc(C(=O)O)cc1)COc1cccc2ccccc12)C(C)C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX3 P56373 2/20 0.45
KDM4E B2RXH2 3/20 0.44
ALDH1A1 P00352 3/20 0.44
HPGD P15428 3/20 0.44
TDP1 Q9NUW8 1/20 0.44
DAPK1 P53355 1/20 0.42
PIM3 Q86V86 1/20 0.42
KMT2A Q03164 4/20 0.41
MEN1 O00255 3/20 0.41
MAPT P10636 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
POLB P06746 1/20 0.41
MAPK1 P28482 1/20 0.41
BLM P54132 1/20 0.41
MRGPRX4 Q96LA9 1/20 0.41
TSHR P16473 1/20 0.40
OGG1 O15527 1/20 0.39
LMNA P02545 1/20 0.37
PIN1 Q13526 1/20 0.37
CASP3 P42574 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1307026 1.00 P2RX3 (0.45) P2RX3KDM4EALDH1A1HPGDTDP1
SCHEMBL1306014 0.91 P2RX3 (0.53) P2RX3KDM4EALDH1A1HPGDTDP1
SCHEMBL1306017 0.91 P2RX3 (0.53) P2RX3KDM4EALDH1A1HPGDTDP1
SCHEMBL1306019 0.91 P2RX3 (0.53) P2RX3KDM4EALDH1A1HPGDTDP1
SCHEMBL5796084 0.83 P2RX3 (0.47) P2RX3KDM4EALDH1A1HPGDTDP1
SCHEMBL1306385 0.81 KMT2A (0.48) P2RX3KDM4EALDH1A1HPGDTDP1
SCHEMBL1306387 0.81 KMT2A (0.48) P2RX3KDM4EALDH1A1HPGDTDP1
SCHEMBL1306502 0.80 ALDH1A1 (0.46) KDM4EALDH1A1HPGDTDP1KMT2A
SCHEMBL1306497 0.80 ALDH1A1 (0.46) KDM4EALDH1A1HPGDTDP1KMT2A
SCHEMBL1306493 0.80 ALDH1A1 (0.46) KDM4EALDH1A1HPGDTDP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2913322-A2 Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same Korea Research Institute Of Chemical Technology (KR) 2015-09-02 EP disclosed
US-8053435-B2 Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2011-11-08 US disclosed
US-20100069630-A1 NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-03-18 US disclosed
EP-2089354-A1 NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME Korea Research Institute Of Chemical Technology (KR) 2009-08-19 EP disclosed
WO-2008054154-A1 NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069630-A1 NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME HDAC1, HDAC3, HDAC11 P2RX3 4630/4885KDM4E 125/4885ALDH1A1 673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.